Gemini Therapeutics

48 articles with Gemini Therapeutics

• Gemini Therapeutics Reports 2021 Financial Results

  3/10/2022

  Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021.

• 

  Gemini Axes 80% of Workforce, Names Interim CEO, in Restructuring 

  3/1/2022

  Gemini will undertake a corporate restructuring that will see a drastic 80% of its workforce laid off. 

• Gemini Therapeutics Provides Corporate Update - Feb 28, 2022

  2/28/2022

  Gemini Therapeutics, Inc., a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration, provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring.

• Gemini Therapeutics Provides GEM103 Program Update

  1/10/2022

  Gemini Therapeutics, Inc. today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103’s clinical development program.

• Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/15/2021

  Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

• Gemini Therapeutics Announces Poster Presentation at AAO 2021

  11/12/2021

  Gemini Therapeutics, Inc. today announced that Raj Maturi, M.D., will present a poster at the 2021 Annual Meeting of the American Academy of Ophthalmology

• Gemini Therapeutics to Participate in Upcoming Investor Conferences - Nov 11, 2021

  11/11/2021

  Gemini Therapeutics, Inc., a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration, announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November:

• Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit

  10/19/2021

  Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit

• Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

  10/14/2021

  Gemini Therapeutics, Inc. today announced the grant of inducement awards under Gemini’s 2021 Inducement Plan to two new employees of options to purchase an aggregate of 217,000 shares of Gemini’s common stock.

• 

  Gemini Will Cut 20% of Staff, Pivot All Resources to Geographic Atrophy

  10/6/2021

  ​The company announced that they are reducing its employee headcount and ceasing some of its research programs to focus on its geographic atrophy (GA) trial. 

• Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy

  10/5/2021

  Gemini Therapeutics, Inc. today announced a corporate restructuring, including several executive officer transitions, to prioritize assets and focus on initiating and executing GEM103’s resource-intensive pivotal trial in geographic atrophy (GA).

• 

  Lightstone Increases High-Impact Technologies Portfolio with $375M in New Funding

  9/14/2021

  ​Lightstone Ventures recently announced the closing of Lightstone Ventures III, securing $375 million to invest in early-stage firms that develop high-impact technologies that can change lives. 

• Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics

  9/10/2021

  Gemini Therapeutics, Inc. today announced one oral presentation and the presentation of three posters at the 13th International Conference on Complement Therapeutics held in Ioannina, Greece from September 8-13, 2021.

• Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual

  9/9/2021

  Gemini Therapeutics, Inc. (Nasdaq: GMTX), today announced that Raj Maturi, M.D., Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, presented Gemini’s previously released initial results from its ongoing Phase 2a study at EURETINA 2021 Virtual held from September 9-12, 2021.

• Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  Gemini Therapeutics, Inc., a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration, announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the H.C. Wainwright 23rd Annual Global Investment Conference.

• Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit

  8/30/2021

  Gemini Therapeutics, Inc., a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration, announced that Chief Executive Officer, Jason Meyenburg, and Chief Medical Officer, Samuel Barone, M.D., presented in panel discussions at the Clinical Trials at the Summit on August 28, 2021.

• Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/12/2021

  Gemini Therapeutics, Inc. today reported its financial results for the second quarter ended June 30, 2021 and provided a business update.

• Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference

  8/10/2021

  Gemini Therapeutics, Inc. today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the H.C. Wainwright Ophthalmology Conference on Tuesday, August 17 at 9:00 AM ET.

• Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

  6/22/2021

  Gemini Therapeutics, Inc today announced initial data from its Phase 2a ReGAtta study of GEM103 as of May 2021 in patients with geographic atrophy (GA) secondary to dry AMD.

• Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

  5/26/2021

  Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 3:30 PM ET.